Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5207169 | 0.99 | DPP4 (0.98) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5802541 | 0.89 | DPP4 (0.80) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5805098 | 0.89 | DPP4 (0.80) | DPP4FAPDPP8DPP9 | |
| SCHEMBL3940070 | 0.88 | DPP4 (0.79) | DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5207185 | 0.88 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6166027 | 0.88 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| SCHEMBL5819186 | 0.85 | DPP4 (0.74) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5203503 | 0.85 | DPP4 (1.00) | DPP4FAPDPP8DPP9 | |
| SCHEMBL5819184 | 0.85 | DPP4 (0.74) | DPP4FAPDPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5206572 | 0.84 | DPP4 (0.98) | DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1671649-B1 | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure | TAKEDA PHARMACEUTICAL (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| EP-1671649-A1 | REMEDY FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060039974-A1 | Sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1537880-A1 | SUSTAINED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072810-A1 | Agent for treating diabetes | IAPP, DPP4, GLP1R | DPP4 2/4885FAP 202/4885DPP8 7/4885 |
| US-20060039974-A1 | Sustained release preparation | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 27/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.